Join to View Full Profile
5481 S Maryland AveApt 2Chicago, IL 60637
Dr. Howard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Fred Howard, MD, is an oncology specialist located in Chicago, IL, with a subspecialty in breast cancer. He graduated from the University of Michigan Medical School in 2015. His recent publications include research on trends in breast cancer care and the application of AI to predict outcomes published in well-regarded journals such as JAMA Oncology and Nature Communications.
Education & Training
University of Michigan Medical SchoolClass of 2015
Certifications & Licensure
IL State Medical License 2019 - 2026
IN State Medical License 2023 - 2025
CT State Medical License 2018 - 2020
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.Nan Chen, Margarite Matossian, Poornima Saha, Murtuza Rampurwala, Salaija Kamaraju
Breast Cancer Research and Treatment. 2025-05-01 - 1 citationsAnalysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.Hanna M Hieromnimon, Anna Trzcinska, Frank T Wen, Frederick M Howard, James M Dolezal
Oral Oncology. 2025-04-01 - Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US.Jincong Q Freeman, Dezheng Huo, Sarah P Shubeck, Nan Chen, Sudha R Yarlagadda
JAMA Network Open. 2025-02-03
Press Mentions
Uncovering Inequalities in Breast Cancer Immunotherapy AccessFebruary 17th, 2025- Black Patients with Triple-Negative Breast Cancer May Be Less Likely to Receive Immunotherapy Than White PatientsSeptember 21st, 2024
- Oncology's Largest Annual Meeting Brings 40,000 to Chicago to Discuss Cancer AdvancesJuly 10th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
